---
title: "Guotai Haitong Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)"
description: "Guotai Haitong has reaffirmed its Buy rating for BeOne Medicines Ltd (6160), setting a price target of HK$212.09, while the stock closed at HK$192.30. The analyst consensus is a Strong Buy with an ave"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277311616.md"
published_at: "2026-02-28T14:26:53.000Z"
---

# Guotai Haitong Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)

> Guotai Haitong has reaffirmed its Buy rating for BeOne Medicines Ltd (6160), setting a price target of HK$212.09, while the stock closed at HK$192.30. The analyst consensus is a Strong Buy with an average target of HK$244.52, indicating a potential upside of 27.16%. Additionally, DBS also maintains a Buy rating with a higher price target of HK$290.00.

In a report released yesterday, from Guotai Haitong maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$212.09. The company’s shares closed yesterday at HK$192.30.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Currently, the analyst consensus on BeOne Medicines Ltd is a Strong Buy with an average price target of HK$244.52, representing a 27.16% upside. In a report released yesterday, DBS also maintained a Buy rating on the stock with a HK$290.00 price target.

### Related Stocks

- [ONC.US - Beigene](https://longbridge.com/en/quote/ONC.US.md)
- [06160.HK - BEONE MEDICINES](https://longbridge.com/en/quote/06160.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BeOne Medicines posts 2025 results and issues cautious 2026 outlook | BeOne Medicines Ltd, a biopharmaceutical company based in Switzerland and listed in Hong Kong, has released its unaudite | [Link](https://longbridge.com/en/news/277035413.md) |
| Guotai Haitong Remains a Buy on Zai Lab Ltd (1ZLB) | Guotai Haitong analyst maintained a Buy rating on Zai Lab Ltd yesterday and set a price target of HK$27.94.Claim 50% Off | [Link](https://longbridge.com/en/news/277338249.md) |
| Nine Dragons Paper Holdings (NDGPF) Receives a Buy from GF Securities | GF Securities analyst maintained a Buy rating on Nine Dragons Paper Holdings yesterday and set a price target of HK$9.87 | [Link](https://longbridge.com/en/news/277339226.md) |
| CICC Reaffirms Their Buy Rating on JNBY Design (JNBYF) | CICC has reaffirmed a Buy rating on JNBY Design (JNBYF) with a price target of HK$24.97, while the shares closed at HK$2 | [Link](https://longbridge.com/en/news/277274710.md) |
| Emperor Securities Keeps Their Buy Rating on Concord New Energy Group (CWPWF) | Emperor Securities analyst maintained a Buy rating on Concord New Energy Group yesterday and set a price target of HK$0. | [Link](https://longbridge.com/en/news/277338692.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.